معرفی
Eric Hoyeon Song is an Assistant Professor Adjunct in the Department of Ophthalmology & Visual Science and Immunobiology at Yale School of Medicine. He is a physician-scientist with a dual MD-PhD degree, currently completing his residency at Yale New Haven Hospital and serving as Chief Resident. His research program focuses on understanding and modulating immune responses in immune-privileged tissues, particularly the brain and eye, integrating immunology, bioengineering, and clinical medicine.
Education:
- MD, Yale University (2022)
- PhD, Immunobiology, Yale University (2020)
- MS, Johns Hopkins University (2015)
- BS, Biochemistry, University of Southern California (2014)
Dr. Song's research interests lie at the intersection of neuroimmunology, ocular immunology, and bioengineering. His lab investigates how immune privilege is maintained in the brain and eye, and how disruptions contribute to disease. He has made significant contributions to understanding the ocular lymphatic system, neuroinvasion of SARS-CoV-2, and lymphatic modulation in brain tumors and stroke. His work employs advanced techniques including single-cell analysis, synthetic biology, and nanoparticle engineering.
His recent publications, appearing in journals like Nature and Journal of Experimental Medicine, reveal a strong trend toward understanding the role of lymphatic and immune interactions in neurological and ocular diseases. Key themes include the eye-brain immune axis, neuroinflammation, viral neuroinvasion, and the development of novel tools for immunomodulation and drug delivery.
Dr. Song has not received any publicly listed scientific awards in the provided text.
He is actively involved in clinical training as a resident physician and leads a vibrant research laboratory. His work is supported by his appointments at Yale and affiliations with Palade House. He mentors students and researchers in his lab, though specific advisees are not listed. Future directions likely include translating his discoveries into therapies for neurodegenerative diseases, autoimmune conditions, and cancers affecting immune-privileged sites.
